Merck (MRK) Q3 2026: revenue above expectations, adjusted EPS beats consensus
FROM THE WIRE · FINANCE.YAHOO.COM
MRK Q3 deep dive: oncology launches, clinical pipeline advances, and margin headwinds Global pharmaceutical company Merck (NYSE:MRK) reported revenue ahead of Wall Street's expectations in Q3 2026, with sales up 4.7% year on year to $18.09 billion. The company expects the full…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA quarter ahead of expectations for a large pharma company can support the stock, although margins remain under pressure.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Third-quarter revenue was 18.09 billion dollars, up 4.7% year on year.
- 02Non-GAAP earnings per share were 2.49 dollars, 19.3% above analyst consensus.
- 03Full-year revenue guidance was slightly raised to 67.05 billion dollars at the midpoint.
- 04Management also raised adjusted EPS guidance.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Merck & Co., Inc.149.52 USDMarket closedtoday +2.18%Positive Merck & Company Inc49,660.00 ARSMarket closedtoday +3.07%Positive Merck & Company Inc2,814.00 MXNMarket closedtoday +1.22%Positive Merck & Company Inc134.54 EURMarket closedtoday +1.42%Positive Merck & Co. Inc134.60 EURMarket closedtoday +1.58%Positive Merck & Co. Inc100.15 BRLMarket closedtoday +1.16%Positive
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets